Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Biosimilar-focused biopharmaceutical company and contract development and manufacturing organization (CDMO) Tanvex BioPharma has named Stephen Lam its new chief executive (CEO). 5 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024
Urica Therapeutics, a Fortress Biotech company focused on the development and commercialization of products for gout and chronic kidney disease, has announced the appointments of Jay Kranzler as chairman and chief executive, and Vibeke Strand to its board of directors. 3 October 2022
Cambridge, USA-base immuno-oncology company DEM BioPharma has appointment of Nenad Grmusa as chief executive and Christophe Quéva, as chief scientific officer. 27 September 2022
Belgium’s NeuVasQ Biotechnologies, a Université Libre de Bruxelles (ULB) spin-off developing pharmaceuticals to restore blood-brain barrier function, has named Emmanuel Lacroix chief executive and company director. 20 September 2022
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announced the appointment of Susan Nichols to its senior management team as chief business officer (CBO). 20 September 2022
Privately-held US CAR-T company ImmPACT Bio has tasked Jonathan Benjamin with leading its clinical development strategy as the company’s chief medical officer. 14 September 2022
French biotech GenSight Biologics, which is developing gene therapy for rare and neurodegenerative diseases of the eye, is adding to its management team in anticipation of the European commercialization of Lumevoq (lenadogene nolparvovec). 13 September 2022
American president Joe Biden has announced his intent to appoint Dr Renee Wegrzyn as the first director of the Advanced Research Projects Agency for Health (ARPA-H), a new agency established to drive biomedical innovation that supports the health of all Americans. 13 September 2022
Lonza, a major Swiss contract development and manufacturing organization, has appointed Daniel Palmacci as president of its Cell and Gene Division. He will take over the role from Jean-Christophe Hyvert, who will continue to serve as president of Lonza’s Biologics Division. 12 September 2022
US biotech Vertex Pharmaceuticals today announced that Jonathan Biller has been appointed chief legal officer, effective September 19, 2022. 8 September 2022
STORM Therapeutics, a UK biotech discovering and developing small molecule therapies targeting RNA modification enzymes for oncology and other diseases, has announced the appointment of Gerald McMahon as president, chief executive and board director. 7 September 2022
Nodus Oncology, a novel biotech company focused on developing first and best-in-class molecules inhibiting novel DNA damage response (DDR) targets, has launched with seed funding from Cumulus Oncology and announced a partnership with the Lead Discovery Center (LDC). 6 September 2022
The Drugs for Neglected Diseases initiative (DNDi) has announced Dr Luis Pizarro as its new executive director, who will replace Bernard Pécoul, who has served in the role for almost 20 years. 5 September 2022
A new chapter opens at privately-held Italian drugmaker Chiesi Farmaceutici as the 11-year tenure of chief executive Ugo Di Francesco, aged 62, comes to a close at the end of 2022. 5 September 2022
Private equity firm Permira, in partnership with the Marcucci family and supported by their co-investors, have completed the joint acquisition and combination of Kedrion Biopharma and Bio Products Laboratory (BPL). 1 September 2022
Ocugen, a US biotech focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, has announced the appointment of Robert Hopkins as chief medical officer (CMO) and Arun Upadhyay as chief scientific officer (CSO). 1 September 2022